 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have completed the initial in silico screening process of their drug discovery program and have identified an additional specific compound, as well as multiple analogs, that could function as inhibitors of the main protease Mpro of the virus. As previously announced, Anixa and OntoChem have identified four compounds that could disrupt the function of a viral enzyme called an endoribonuclease also known as Non-Structural Protein-15, or NSP-15. 